Nothing Special   »   [go: up one dir, main page]

Schildknecht et al., 2017 - Google Patents

Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP

Schildknecht et al., 2017

View PDF
Document ID
16047740225201117534
Author
Schildknecht S
Di Monte D
Pape R
Tieu K
Leist M
Publication year
Publication venue
Trends in Pharmacological Sciences

External Links

Snippet

The neurotoxicant 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) causes a Parkinson's disease (PD)-like syndrome by inducing degeneration of nigrostriatal dopaminergic neurons. Studies of the MPTP model have revealed the pathomechanisms …
Continue reading at kops.uni-konstanz.de (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Schildknecht et al. Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP
Grünewald et al. New insights into the complex role of mitochondria in Parkinson’s disease
Caudle et al. Altered vesicular dopamine storage in Parkinson's disease: a premature demise
Goguadze et al. Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress
Puspita et al. Oxidative stress and cellular pathologies in Parkinson’s disease
Masato et al. Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Malpartida et al. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: from mechanism to therapy
Lohr et al. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Chen et al. Interactions between iron and α-synuclein pathology in Parkinson's disease
Ge et al. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease
Mercado et al. An ERcentric view of Parkinson's disease
Bendotti et al. Lessons from models of SOD1-linked familial ALS
Scarffe et al. Parkin and PINK1: much more than mitophagy
Núñez et al. Iron toxicity in neurodegeneration
Aflaki et al. The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease
Yun et al. Mitohormesis
Ryan et al. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Bell et al. CNS peroxiredoxins and their regulation in health and disease
Mosharov et al. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons
Qin et al. Chronic stress induces anxiety via an amygdalar intracellular cascade that impairs endocannabinoid signaling
Surmeier et al. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease
Sulzer Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Di Carlo et al. Are oxidative stress and mitochondrial dysfunction the key players in the neurodegenerative diseases?
Toescu et al. Ca2+ regulation and gene expression in normal brain aging
Olivares et al. Physiological and pathological role of alpha-synuclein in Parkinson’s disease through iron mediated oxidative stress; the role of a putative iron-responsive element